The DOI matches its Crossref record; 151 of the 151 references it cites were found in a registry or an index.
Drug resistance in multiple myeloma
Abstract
Multiple myeloma (MM, plasma cell myeloma) is a malignant hematologic disease characterized by the clonal proliferation of malignant plasma cells. The treatment of MM has changed dramatically in recent years, with the introduction of new drugs into therapeutic strategies, both in the front line setting and in relapsed refractory disease. However, most patients eventually relapse and often demonstrate multiple drug resistance. Therefore there is still an urgent and unmet need to define the molecular mechanisms of resistance for available drugs in order to enhance the use of existing treatments and design more effective therapies. Genetic abnormalities are well known to play a central role in MM resistance to available drugs, and epigenetic aberrations mainly affecting the patterns of DNA methylation and histone modifications of genes, especially tumor suppressors, can be involved in the resistance mechanism. Moreover, defects in the mechanisms of apoptosis, senescence and DNA repair could also contribute to drug resistance. In addition, mutations or alterations in the expression of the drug target can influence response to therapy. Achieving a better understanding of the pathways and protein expression involved in MM drug resistance and the development of novel therapeutic strategies are important goals for further progress in the treatment of MM. This review gives a critical overview of the role of cellular, microenvironmental and molecular mechanisms of drug resistance in MM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Swerdlow, S. H., Campo, E., Pileri, S. A., Harris, N. L., Stein, H., Siebert, R., Advani, R., Ghielmini, M., Salles, G. A., Zelenetz, A. D., et al. (2016) · Blood · doi:10.1182/blood-2016-01-643569 · Cited by 7,831
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Palumbo, A., & Anderson, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,326
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
Hypoxia, HIF1 and glucose metabolism in the solid tumour
Denko, N. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2468 · Cited by 1,707
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606038 · Cited by 1,522
Kumar, S. K., Dispenzieri, A., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Pandey, S., Kapoor, P., Dingli, D., Hayman, S. R., Leung, N., et al. (2014) · Leukemia · doi:10.1038/leu.2013.313 · Cited by 1,369
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505654 · Cited by 1,322
Plasma cell differentiation requires the transcription factor XBP-1
Reimold, A. M., Iwakoshi, N. N., Manis, J., Vallabhajosyula, P., Szomolanyi-Tsuda, E., Gravallese, E. M., Friend, D., Grusby, M. J., Alt, F., & Glimcher, L. H. (2001) · Nature · doi:10.1038/35085509 · Cited by 1,305
Sampaio, E. P., Sarno, E. N., Galilly, R., Cohn, Z. A., & Kaplan, G. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.3.699 · Cited by 1,192
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
Obeng, E. A., Carlson, L. M., Gutman, D. M., Harrington, W. J., Lee, K. P., & Boise, L. H. (2006) · Blood · doi:10.1182/blood-2005-08-3531 · Cited by 1,143
Covalent histone modifications — miswritten, misinterpreted and mis-erased in human cancers
Chi, P., Allis, C. D., & Wang, G. G. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2876 · Cited by 1,099
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Moreau, P., Masszi, T., Grzasko, N., Bahlis, N. J., Hansson, M., Pour, L., Sandhu, I., Ganly, P., Baker, B. W., Jackson, S. R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516282 · Cited by 1,060
de Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
Lohr, J. G., Stojanov, P., Carter, S. L., Cruz-Gordillo, P., Lawrence, M. S., Auclair, D., Sougnez, C., Knoechel, B., Gould, J., Saksena, G., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2013.12.015 · Cited by 988
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
Mateos, M.-V., Dimopoulos, M. A., Cavo, M., Suzuki, K., Jakubowiak, A., Knop, S., Doyen, C., Lucio, P., Nagy, Z., Kaplan, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714678 · Cited by 988
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G., & Anderson, K. C. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2189 · Cited by 932
Damiano, J. S., Cress, A. E., Hazlehurst, L. A., Shtil, A. A., & Dalton, W. S. (1999) · Blood · doi:10.1182/blood.v93.5.1658 · Cited by 901
Dimopoulos, M. A., Moreau, P., Palumbo, A., Joshua, D., Pour, L., Hájek, R., Facon, T., Ludwig, H., Oriol, A., Goldschmidt, H., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00464-7 · Cited by 857
Molecular sequelae of proteasome inhibition in human multiple myeloma cells
Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., Libermann, T. A., Treon, S. P., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202445099 · Cited by 741
IRF4 addiction in multiple myeloma
Shaffer, A. L., Emre, N. C. T., Lamy, L., Ngo, V. N., Wright, G., Xiao, W., Powell, J., Dave, S., Yu, X., Zhao, H., et al. (2008) · Nature · doi:10.1038/nature07064 · Cited by 730
Kumar, S. K., Lee, J. H., Lahuerta, J. J., Morgan, G., Richardson, P. G., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., et al. (2012) · Leukemia · doi:10.1038/leu.2011.196 · Cited by 721
Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Richardson, P. G., Hideshima, T., Munshi, N. C., Treon, S. P., & Anderson, K. C. (2002) · Blood · doi:10.1182/blood.v99.12.4525 · Cited by 669
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
Zhu, Y. X., Braggio, E., Shi, C.-X., Bruins, L. A., Schmidt, J. E., Van Wier, S., Chang, X.-B., Bjorklund, C. C., Fonseca, R., Bergsagel, P. L., et al. (2011) · Blood · doi:10.1182/blood-2011-05-356063 · Cited by 607
Hideshima, T., Bradner, J. E., Wong, J., Chauhan, D., Richardson, P., Schreiber, S. L., & Anderson, K. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503221102 · Cited by 593
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341
Hideshima, T., Mitsiades, C., Akiyama, M., Hayashi, T., Chauhan, D., Richardson, P., Schlossman, R., Podar, K., Munshi, N. C., Mitsiades, N., et al. (2003) · Blood · doi:10.1182/blood-2002-08-2543 · Cited by 566
Chamberlain, P. P., Lopez-Girona, A., Miller, K., Carmel, G., Pagarigan, B., Chie-Leon, B., Rychak, E., Corral, L. G., Ren, Y. J., Wang, M., et al. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2874 · Cited by 531
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma
Kumar, S., Kaufman, J. L., Gasparetto, C., Mikhael, J., Vij, R., Pegourie, B., Benboubker, L., Facon, T., Amiot, M., Moreau, P., et al. (2017) · Blood · doi:10.1182/blood-2017-06-788786 · Cited by 523
Overdijk, M. B., Verploegen, S., Bögels, M., van Egmond, M., van Bueren, J. J. L., Mutis, T., Groen, R. W., Breij, E., Martens, A. C., Bleeker, W. K., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1007813 · Cited by 521
Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma
Hideshima, T., Nakamura, N., Chauhan, D., & Anderson, K. C. (2001) · Oncogene · doi:10.1038/sj.onc.1204833 · Cited by 478
Tai, Y.-T., Dillon, M., Song, W., Leiba, M., Li, X.-F., Burger, P., Lee, A. I., Podar, K., Hideshima, T., Rice, A. G., et al. (2008) · Blood · doi:10.1182/blood-2007-08-107292 · Cited by 473
Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy
Gabizon, A. A. (2001) · Cancer Investigation · doi:10.1081/cnv-100103136 · Cited by 458
Oerlemans, R., Franke, N. E., Assaraf, Y. G., Cloos, J., van Zantwijk, I., Berkers, C. R., Scheffer, G. L., Debipersad, K., Vojtekova, K., Lemos, C., et al. (2008) · Blood · doi:10.1182/blood-2007-08-104950 · Cited by 454
Wang, J., Hendrix, A., Hernot, S., Lemaire, M., De Bruyne, E., Van Valckenborgh, E., Lahoutte, T., De Wever, O., Vanderkerken, K., & Menu, E. (2014) · Blood · doi:10.1182/blood-2014-03-562439 · Cited by 441
Azab, A. K., Runnels, J. M., Pitsillides, C., Moreau, A.-S., Azab, F., Leleu, X., Jia, X., Wright, R., Ospina, B., Carlson, A. L., et al. (2009) · Blood · doi:10.1182/blood-2008-10-186668 · Cited by 428
De Keersmaecker, K., Atak, Z. K., Li, N., Vicente, C., Patchett, S., Girardi, T., Gianfelici, V., Geerdens, E., Clappier, E., Porcu, M., et al. (2013) · Nature Genetics · doi:10.1038/ng.2508 · Cited by 428
Nijhof, I. S., Casneuf, T., van Velzen, J., van Kessel, B., Axel, A. E., Syed, K., Groen, R. W. J., van Duin, M., Sonneveld, P., Minnema, M. C., et al. (2016) · Blood · doi:10.1182/blood-2016-03-703439 · Cited by 393
Leung-Hagesteijn, C., Erdmann, N., Cheung, G., Keats, J. J., Stewart, A. K., Reece, D. E., Chung, K. C., & Tiedemann, R. E. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.009 · Cited by 383
Li, T., Li, D., Sha, J., Sun, P., & Huang, Y. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.03.077 · Cited by 370
Clinical Course of Patients With Relapsed Multiple Myeloma
Kumar, S. K., Therneau, T. M., Gertz, M. A., Lacy, M. Q., Dispenzieri, A., Rajkumar, S. V., Fonseca, R., Witzig, T. E., Lust, J. A., Larson, D. R., et al. (2004) · Mayo Clinic Proceedings · doi:10.4065/79.7.867 · Cited by 365
Chaudhary, P. M., & Roninson, I. B. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.8.632 · Cited by 360
Kapahi, P., Takahashi, T., Natoli, G., Adams, S. R., Chen, Y., Tsien, R. Y., & Karin, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m007204200 · Cited by 359
Palumbo, A., Bringhen, S., Ludwig, H., Dimopoulos, M. A., Bladé, J., Mateos, M. V., Rosiñol, L., Boccadoro, M., Cavo, M., Lokhorst, H., et al. (2011) · Blood · doi:10.1182/blood-2011-06-358812 · Cited by 352
Zonder, J. A., Mohrbacher, A. F., Singhal, S., van Rhee, F., Bensinger, W. I., Ding, H., Fry, J., Afar, D. E. H., & Singhal, A. K. (2012) · Blood · doi:10.1182/blood-2011-06-360552 · Cited by 342
Bone marrow microenvironment and the identification of new targets for myeloma therapy
Podar, K., Chauhan, D., & Anderson, K. C. (2009) · Leukemia · doi:10.1038/leu.2008.259 · Cited by 337
Modulation of multidrug-resistant multiple myeloma by cyclosporin
Sonneveld, P., Lowenberg, B., Durie, B. G. M., Lokhorst, H. M., Marie, J.-P., Zittoun, R., Solbu, G., Suciu, S., & Nooter, K. (1992) · The Lancet · doi:10.1016/0140-6736(92)92353-h · Cited by 316
Overdijk, M. B., Jansen, J. H. M., Nederend, M., Lammerts van Bueren, J. J., Groen, R. W. J., Parren, P. W. H. I., Leusen, J. H. W., & Boross, P. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501351 · Cited by 297
Moreau, P., Chanan-Khan, A., Roberts, A. W., Agarwal, A. B., Facon, T., Kumar, S., Touzeau, C., Punnoose, E. A., Cordero, J., Munasinghe, W., et al. (2017) · Blood · doi:10.1182/blood-2017-06-788323 · Cited by 271
Nijhof, I. S., Groen, R. W. J., Lokhorst, H. M., van Kessel, B., Bloem, A. C., van Velzen, J., de Jong-Korlaar, R., Yuan, H., Noort, W. A., Klein, S. K., et al. (2015) · Leukemia · doi:10.1038/leu.2015.123 · Cited by 267
Kortüm, K. M., Mai, E. K., Hanafiah, N. H., Shi, C.-X., Zhu, Y.-X., Bruins, L., Barrio, S., Jedlowski, P., Merz, M., Xu, J., et al. (2016) · Blood · doi:10.1182/blood-2016-02-698092 · Cited by 255
Epidemiology of Multiple Myeloma
Becker, N. (2011) · Recent Results in Cancer Research · doi:10.1007/978-3-540-85772-3_2 · Cited by 228
Regulation of the Complement Membrane Attack Pathway
Morgan, B. P. (1999) · Critical Reviews™ in Immunology · doi:10.1615/critrevimmunol.v19.i3.10 · Cited by 222
Metabolic Signature Identifies Novel Targets for Drug Resistance in Multiple Myeloma
Maiso, P., Huynh, D., Moschetta, M., Sacco, A., Aljawai, Y., Mishima, Y., Asara, J. M., Roccaro, A. M., Kimmelman, A. C., & Ghobrial, I. M. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3400 · Cited by 208
Current treatment landscape for relapsed and/or refractory multiple myeloma
Dimopoulos, M. A., Richardson, P. G., Moreau, P., & Anderson, K. C. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.200 · Cited by 195
Molecular basis of resistance to proteasome inhibitors in hematological malignancies
Niewerth, D., Jansen, G., Assaraf, Y. G., Zweegman, S., Kaspers, G. J. L., & Cloos, J. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2014.12.001 · Cited by 189
ABCG2 expression, function, and promoter methylation in human multiple myeloma
Turner, J. G., Gump, J. L., Zhang, C., Cook, J. M., Marchion, D., Hazlehurst, L., Munster, P., Schell, M. J., Dalton, W. S., & Sullivan, D. M. (2006) · Blood · doi:10.1182/blood-2005-10-009084 · Cited by 189
Modulation of multidrug resistance: at the threshold.
Sikic, B. I. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.9.1629 · Cited by 182
Franke, N. E., Niewerth, D., Assaraf, Y. G., van Meerloo, J., Vojtekova, K., van Zantwijk, C. H., Zweegman, S., Chan, E. T., Kirk, C. J., Geerke, D. P., et al. (2012) · Leukemia · doi:10.1038/leu.2011.256 · Cited by 175
Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms
Abdi, J., Chen, G., & Chang, H. (2013) · Oncotarget · doi:10.18632/oncotarget.1497 · Cited by 172
Tai, Y.-T., Chang, B. Y., Kong, S.-Y., Fulciniti, M., Yang, G., Calle, Y., Hu, Y., Lin, J., Zhao, J.-J., Cagnetta, A., et al. (2012) · Blood · doi:10.1182/blood-2011-12-396853 · Cited by 165
Myeloma today: Disease definitions and treatment advances
Rajkumar, S. V. (2016) · American Journal of Hematology · doi:10.1002/ajh.24236 · Cited by 160
Dalton, W. S., Crowley, J. J., Salmon, S., Grogan, T. M., Laufman, L. R., Weiss, G. R., & Bonnet, J. D. (1995) · Cancer · Cited by 158
Richardson, P. G. G., Jagannath, S., Moreau, P., Jakubowiak, A. J., Raab, M. S., Facon, T. T. F., Vij, R., White, D. J., Reece, D. E., Benboubker, L., et al. (2015) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00197-0 · Cited by 158
Wang, J., Veirman, K. D., Beule, N. D., Maes, K., Bruyne, E. D., Valckenborgh, E. V., Vanderkerken, K., & Menu, E. (2015) · Oncotarget · doi:10.18632/oncotarget.6083 · Cited by 155
Hideshima, T., Qi, J., Paranal, R. M., Tang, W., Greenberg, E. F., West, N. H., Colling, M. E., Estiu, G. L., Mazitschek, R., Perry, J. A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608067113 · Cited by 151
Characterization of the ubiquitin–proteasome system in bortezomib-adapted cells
Rückrich, T., Kraus, M., Gogel, J., Beck, A., Ovaa, H., Verdoes, M., Overkleeft, H. S., Kalbacher, H., & Driessen, C. (2009) · Leukemia · doi:10.1038/leu.2009.8 · Cited by 146
Pharmacological considerations in the modulation of multidrug resistance
Fisher, G. A., Lum, B. L., Hausdorff, J., & Sikic, B. I. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00111-6 · Cited by 133
Hazlehurst, L., Valkov, N. I., Wisner, L., Storey, J. A., Boulware, D. C., Sullivan, D. M., & Dalton, W. S. (2001) · Blood · doi:10.1182/blood.v98.6.1897 · Cited by 132
Treatment Options for Relapsed and Refractory Multiple Myeloma
Lonial, S., Mitsiades, C. S., & Richardson, P. G. G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1805 · Cited by 130
The ribosomal protein gene RPL5 is a haploinsufficient tumor suppressor in multiple cancer types
Fancello, L., Kampen, K. R., Hofman, I. J., Verbeeck, J., & Keersmaecker, K. D. (2017) · Oncotarget · doi:10.18632/oncotarget.14895 · Cited by 126
Bešše, A., Stolze, S. C., Rasche, L., Weinhold, N., Morgan, G. J., Kraus, M., Bader, J. E., Overkleeft, H. S., Bešše, L., & Driessen, C. (2017) · Leukemia · doi:10.1038/leu.2017.212 · Cited by 120
Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer
Meyer, S., Leusen, J. H. W., & Boross, P. (2014) · mAbs · doi:10.4161/mabs.29670 · Cited by 116
Moalli, P., Pillay, S., Weiner, D., Goldman-Leikin, R. E., & Rosen, S. (1992) · Blood · doi:10.1182/blood.v79.1.213.bloodjournal791213 · Cited by 112
Sustained activation of ERK1/2 by NGF induces microRNA‐221 and 222 in PC12 cells
Terasawa, K., Ichimura, A., Sato, F., Shimizu, K., & Tsujimoto, G. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2009.07041.x · Cited by 112
Verbrugge, S. E., Assaraf, Y. G., Dijkmans, B. A. C., Scheffer, G. L., Al, M., den Uyl, D., Oerlemans, R., Chan, E. T., Kirk, C. J., Peters, G. J., et al. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.187542 · Cited by 110
Targeting the Fanconi Anemia/BRCA Pathway Circumvents Drug Resistance in Multiple Myeloma
Yarde, D. N., Oliveira, V. A., Mathews, L., Wang, X., Villagra, A., Boulware, D. C., Shain, K. H., Hazlehurst, L., Alsina, M., Chen, D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2616 · Cited by 110
The role of P-glycoprotein in drug resistance in multiple myeloma
Abraham, J., Salama, N. N., & Azab, A. K. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.907890 · Cited by 106
Qin, Y., Zhang, S., Deng, S., An, G. C., Qin, X., Li, F., Xu, Y., Hao, M., Yang, Y., Zhou, W., et al. (2016) · Leukemia · doi:10.1038/leu.2016.325 · Cited by 99
Zhao, J., Chu, Z., Hu, Y., Lin, J., Wang, Z., Jiang, M., Chen, M., Wang, X., Kang, Y., Zhou, Y., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0457 · Cited by 95
Zhang, X., Baladandayuthapani, V., Lin, H. Y., Mulligan, G., Li, B., Esseltine, D.-L. W., Qi, L., Xu, J., Hunziker, W., Barlogie, B., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.026 · Cited by 94
Molecular mechanisms in multiple myeloma drug resistance
Nikesitch, N., & Ling, S. (2015) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2015-203414 · Cited by 90
Yang, H. H., Ma, M. H., Vescio, R. A., & Berenson, J. R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.001 · Cited by 89
Stein, M., Cui, H., Beck, P., Dubiella, C., Voss, C., Krüger, A., Schmidt, B., & Groll, M. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201308984 · Cited by 87
NF- κ B and chemoresistance: potentiation of cancer drugs via inhibition of NF- κ B
Cusack, J. C., Liu, R., & Baldwin, A. S. (1999) · Drug Resistance Updates · doi:10.1054/drup.1999.0094 · Cited by 86
Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma
Ramani, V. C., Zhan, F., He, J., Barbieri, P., Noseda, A., Tricot, G. J. K., & Sanderson, R. D. (2015) · Oncotarget · doi:10.18632/oncotarget.6408 · Cited by 85
Pick, M., Vainstein, V., Goldschmidt, N., Lavie, D., Libster, D., Gural, A., Grisariu, S., Avni, B. R., Yehuda, D. B., & Gatt, M. E. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13046 · Cited by 85
Richardson, P. G. G., Zimmerman, T. M., Hofmeister, C. C., Talpaz, M., Chanan-Khan, A. A., Kaufman, J. L., Laubach, J. P., Chauhan, D., Jakubowiak, A. J., Reich, S. D., et al. (2016) · Blood · doi:10.1182/blood-2015-12-686378 · Cited by 82
Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model
Stessman, H. A. F., Baughn, L. B., Sarver, A. L., Xia, T., Deshpande, R., Mansoor, A., Walsh, S. A., Sunderland, J. J., Dolloff, N. G., Linden, M. A., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1151 · Cited by 80
Nojima, M., Maruyama, R., Yasui, H., Suzuki, H., Maruyama, Y., Tarasawa, I., Sasaki, Y., Asaoku, H., Sakai, H., Hayashi, T., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3336 · Cited by 80
Li, B.-Z., Fu, J., Chen, P., Ge, X., Li, Y., Kuiatse, I., Wang, H., Wang, H., Zhang, X., & Orlowski, R. Z. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.664953 · Cited by 80
Wuchter, C., Karawajew, L., Ruppert, V., Büchner, T., Schoch, C., Haferlach, T., Ratei, R., Dörken, B., & Ludwig, W.-D. (1999) · Leukemia · doi:10.1038/sj.leu.2401605 · Cited by 80
Molecular Mechanisms of Bortezomib Resistant Adenocarcinoma Cells
Suzuki, É., Demo, S. D., Deu, E., Keats, J. J., Arastu‐Kapur, S., Bergsagel, P. L., Bennett, M. K., & Kirk, C. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027996 · Cited by 78
Waldschmidt, J. M., Simon, A., Wider, D., Müller, S. J., Follo, M., Ihorst, G., Decker, S., Lorenz, J., Chatterjee, M., Azab, A. K., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14807 · Cited by 78
Mechanisms of cell death and survival in multiple myeloma (MM): Therapeutic implications
Chauhan, D., & Anderson, K. C. (2003) · APOPTOSIS · doi:10.1023/a:1024164700094 · Cited by 77
Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells
Hao, M., Zhang, L., An, G., Sui, W., Yu, Z., Zou, D., Xu, Y., Chang, H., & Qiu, L. (2011) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-4-37 · Cited by 77
FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy
Bhatnagar, V., Gormley, N. J., Luo, L., Shen, Y. L., Sridhara, R., Subramaniam, S., Shen, G., Ma, L., Shord, S. S., Goldberg, K. B., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0229 · Cited by 77
Micallef, J., Taccone, M. S., Mukherjee, J., Croul, S. E., Caldwell-Busby, J., Moran, M. F., & Guha, A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4783 · Cited by 76
MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma
Qiang, Y., Ye, S., Chen, Y., Buros, A. F., Edmonson, R., van Rhee, F., Barlogie, B., Epstein, J., Morgan, G. J., & Davies, F. E. (2016) · Blood · doi:10.1182/blood-2016-03-706077 · Cited by 76
Yang, Y., Chen, Y., Saha, M. N., Chen, J., Evans, K., Qiu, L., Reece, D. E., Chen, G. A., & Chang, H. (2014) · Leukemia · doi:10.1038/leu.2014.255 · Cited by 74
Huber, E. M., Heinemeyer, W., & Groll, M. (2015) · Structure · doi:10.1016/j.str.2014.11.019 · Cited by 73
Molecular pathogenesis of multiple myeloma
Furukawa, Y., & Kikuchi, J. (2015) · International Journal of Clinical Oncology · doi:10.1007/s10147-015-0837-0 · Cited by 72
Cheung, W.-C., & Ness, B. V. (2002) · Leukemia · doi:10.1038/sj.leu.2402481 · Cited by 71
Role of epigenetics-microRNA axis in drug resistance of multiple myeloma
Rastgoo, N., Abdi, J., Hou, J., & Chang, H. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0492-1 · Cited by 70
Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma
Furukawa, Y., & Kikuchi, J. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2048-5 · Cited by 67
Dytfeld, D., Łuczak, M., Wróbel, T., Usnarska‐Zubkiewicz, L., Brzeźniakiewicz‐Janus, K., Jamroziak, K., Giannopoulos, K., Przybyłowicz-Chalecka, A., Ratajczak, B., Czerwińska-Rybak, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11059 · Cited by 67
Bellone, S., Roque, D. M., Cocco, E., Gasparrini, S., Bortolomai, I., Buza, N., Abu-Khalaf, M. M., Silasi, D.-A., Ratner, E., Azodi, M., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.132 · Cited by 62
Buda, G., Ricci, D. S., Huang, C., Favis, R., Cohen, N., Zhuang, S. H., Harousseau, J., Sonneveld, P., Bladé, J., & Orlowski, R. Z. (2010) · Annals of Hematology · doi:10.1007/s00277-010-0992-3 · Cited by 62
Hofman, I. J., van Duin, M., Bruyne, E. D., Fancello, L., Mulligan, G., Geerdens, E., Garelli, E., Mancini, C., Lemmens, H., Delforge, M., et al. (2016) · Leukemia · doi:10.1038/leu.2016.370 · Cited by 62
Update on the optimal use of bortezomib in the treatment of multiple myeloma
Mohan, M., Matin, A., & Davies, F. E. (2017) · Cancer Management and Research · doi:10.2147/cmar.s105163 · Cited by 60
Update on the role of lenalidomide in patients with multiple myeloma
Holstein, S. A., Suman, V. J., & McCarthy, P. L. (2018) · Therapeutic Advances in Hematology · doi:10.1177/2040620718775629 · Cited by 60
Moreaux, J., Reme, T. X., Leonard, W., Veyrune, J., Requirand, G., Goldschmidt, H., Hose, D., & Klein, B. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0721 · Cited by 55
VLA-4-Dependent Myeloma Cell Adhesion
Sanz-Rodríguez, F., & Teixidó, J. (2001) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190109057979 · Cited by 54
Levin, N., Spencer, A. G., Harrison, S. J., Chauhan, D., Burrows, F. J., Anderson, K. C., Reich, S. D., Richardson, P. G. G., & Trikha, M. (2016) · British Journal of Haematology · doi:10.1111/bjh.14113 · Cited by 54
Melphalan hydrochloride for the treatment of multiple myeloma
Esma, F., Salvini, M., Troia, R., Boccadoro, M., Larocca, A., & Pautasso, C. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1349102 · Cited by 53
Current use of monoclonal antibodies in the treatment of multiple myeloma
Varga, C., Maglio, M. E., Ghobrial, I. M., & Richardson, P. G. G. (2018) · British Journal of Haematology · doi:10.1111/bjh.15121 · Cited by 53
Kortüm, K. M., Langer, C., Monge, J., Bruins, L. A., Zhu, Y. X., Shi, C. X., Jedlowski, P. M., Egan, J. B., Ojha, J., Bullinger, L., et al. (2015) · Annals of Hematology · doi:10.1007/s00277-015-2344-9 · Cited by 52
Pollett, J. B., Trudel, S., Stern, D., Li, Z.-X., & Stewart, A. K. (2002) · Blood · doi:10.1182/blood-2002-02-0608 · Cited by 51
A novel CXCR4 antagonist IgG1 antibody (PF-06747143) for the treatment of hematologic malignancies
Liu, S., Gu, Y., Pascual, B., Yan, Z., Hallin, M. E., Zhang, C., Fan, C., Wang, W., Lam, J. L., Spilker, M. E., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2016003921 · Cited by 51
Stessman, H. A. F., Mansoor, A., Zhan, F., Janz, S., Linden, M. A., Baughn, L. B., & Ness, B. V. (2013) · Leukemia · doi:10.1038/leu.2013.148 · Cited by 50
PhosphoMARCKS drives motility of mouse melanoma cells
Chen, X., & Rotenberg, S. A. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.03.003 · Cited by 50
Morito, N., Yoh, K., Maeda, A., Nakano, T., Fujita, A., Kusakabe, M., Hamada, M., Kudo, T., Yamagata, K., & Takahashi, S. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1057 · Cited by 50
Niewerth, D., Jansen, G., Riethoff, L. F. V., van Meerloo, J., Kale, A. J., Moore, B. S., Assaraf, Y. G., Anderl, J. L., Zweegman, S., Kaspers, G. J. L., et al. (2014) · Molecular Pharmacology · doi:10.1124/mol.114.092114 · Cited by 47
Ge, X., Wu, L., Hu, W., Fernandes, S. M., Wang, C., Li, X., Brown, J. R., & Qin, X. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0647 · Cited by 44
Rees‐Unwin, K. S., Craven, R. A., Davenport, E. L., Hanrahan, S. J., Totty, N. F., Dring, A. M., Banks, R. E., Morgan, G. J., & Davies, F. E. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06837.x · Cited by 43
Medh, R. D., Wang, A., Zhou, F. L., & Thompson, E. B. (2001) · Oncogene · doi:10.1038/sj.onc.1204680 · Cited by 41
Emerging pathways as individualized therapeutic target of multiple myeloma
Misso, G., Zappavigna, S., Castellano, M., Rosa, G. D., Martino, M. T. D., Tagliaferri, P., Tassone, P., & Caraglia, M. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.807338 · Cited by 40
Overcoming multiple myeloma drug resistance in the era of cancer ‘omics’
Ho, M., McCann, A. H., Bianchi, G., Zhang, L., Dowling, P., Bazou, D., O’Gorman, P., & Anderson, K. C. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1337115 · Cited by 38
Micro-RNAs, New performers in multiple myeloma bone marrow microenvironment
Abdi, J., Qiu, L., & Chang, H. (2014) · Biomarker Research · doi:10.1186/2050-7771-2-10 · Cited by 34
Low frequency mutations in ribosomal proteins RPL10 and RPL5 in multiple myeloma
Hofman, I. J., Patchett, S., van Duin, M., Geerdens, E., Verbeeck, J., Michaux, L., Delforge, M., Sonneveld, P., Johnson, A. M., & Keersmaecker, K. D. (2017) · Haematologica · doi:10.3324/haematol.2016.162198 · Cited by 34
SDZ PSC-833—a novel potent in vitro chemosensitizer in multiple myeloma
Jönsson, B., Nilsson, K., Nygren, P., & Larsson, R. (1992) · Anti-Cancer Drugs · doi:10.1097/00001813-199212000-00013 · Cited by 31
Terragna, C., Remondini, D., Martello, M., Zamagni, E., Pantani, L., Patriarca, F. F., Pezzi, A., Levi, G., Offidani, M., Proserpio, I., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5718 · Cited by 31
Xu, X., Liu, J., Shen, C., Ding, L., Zhong, F., Ouyang, Y., Wang, Y., & He, S. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12729 · Cited by 30
Multiple myeloma L eu167 I le (c.499 C > A ) mutation prevents XBP 1 m RNA splicing
Hong, S. Y., & Hagen, T. (2013) · British Journal of Haematology · doi:10.1111/bjh.12310 · Cited by 29
EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma
Tzogani, K., Penninga, E. I., Christiansen, M. L. S., Hovgaard, D., Sarac, S. B., Jiménez, J. C., Garcia, I., Lafuente, M., Sancho-López, A., Salmonson, T., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0328 · Cited by 28
Fu, J. (2017) · Archives of Medical Science · doi:10.5114/aoms.2017.64722 · Cited by 25
The prognostic significance of 8p21 deletion in multiple myeloma
Sütlü, T., Alici, E., Jansson, M., Wallblom, A., Dilber, M. S., Gahrton, G., & Nahi, H. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07454.x · Cited by 24
Perspectives in the treatment of multiple myeloma
Gentile, M., Recchia, A. G., Mazzone, C., Lucia, E., Vigna, E., & Morabito, F. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.799132 · Cited by 23
Offidani, M., Corvatta, L., Caraffa, P., Leoni, P., Pautasso, C., Larocca, A., & Palumbo, A. P. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.906904 · Cited by 23
Franken, B., van de Donk, N. W. C. J., Cloos, J. J., Zweegman, S., & Lokhorst, H. M. (2016) · Therapeutic Advances in Hematology · doi:10.1177/2040620716667275 · Cited by 21
RECQ helicases are deregulated in hematological malignancies in association with a prognostic value
Viziteu, E., Kassambara, A., Pasero, P., Klein, B., & Moreaux, J. (2016) · Biomarker Research · doi:10.1186/s40364-016-0057-4 · Cited by 20
Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells
Tibullo, D., Rosa, M. D., Giallongo, C., Cava, P. L., Parrinello, N. L., Romano, A., Conticello, C., Brundo, M. V., Saccone, S., Malaguarnera, L., et al. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00226 · Cited by 18
Franke, N. E., Kaspers, G. J. L., Assaraf, Y. G., van Meerloo, J., Niewerth, D., Kessler, F. L., Poddighe, P. J., Kole, J., Smeets, S. J., Ylstra, B., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11340 · Cited by 18
Loeff, F. C., van Egmond, H. M. E., Nijmeijer, B. A., Falkenburg, J. H. F., Halkes, C. J. M., & Jedema, I. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1281411 · Cited by 17
Zheng, Z., Liu, T., Zheng, J., & Hu, J. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s130742 · Cited by 14
Tzogani, K., Jiménez, J. C., Garcia, I., Sancho-López, A., Martin, M., Moreau, A., Démolis, P., Salmonson, T., Bergh, J. C. S., Laane, E., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0184 · Cited by 14
RECQ1 expression is upregulated in response to DNA damage and in a p53-dependent manner
Parvathaneni, S., Lu, X., Chaudhary, R., Lal, A., Madhusudan, S., & Sharma, S. (2017) · Oncotarget · doi:10.18632/oncotarget.18237 · Cited by 11
Ixazomib in the Management of Relapsed Multiple Myeloma
Touzeau, C., & Moreau, P. (2018) · Future Oncology · doi:10.2217/fon-2017-0710 · Cited by 10
Role of IRF4 in resistance to immunomodulatory (IMid) compounds® in Waldenström’s macroglobulinemia
Bertrand, E., Jouy, N., Manier, S., Fouquet, G., Guidez, S., Boyle, E. M., Noel, S., Tomowiak, C., Herbaux, C., Schraen‐Maschke, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22872 · Cited by 8
Cited by
Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance
Narayanan, S., Cai, C.-Y., Assaraf, Y. G., Guo, H.-Q., Cui, Q., Wei, L., Huang, J.-J., Ashby, C. R., & Chen, Z.-S. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100663 · Cited by 332
Cohen, Y. C., Zada, M., Wang, S.-Y., Bornstein, C., David, E., Moshe, A., Li, B., Shlomi-Loubaton, S., Gatt, M. E., Gur, C., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01232-w · Cited by 235
Usmani, S. Z., Quach, H., Mateos, M.-V., Landgren, O., Leleu, X., Siegel, D., Weisel, K., Gavriatopoulou, M., Oriol, A., Rabin, N., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00579-9 · Cited by 171
Siegel, D. S., Schiller, G. J., Song, K. W., Agajanian, R., Stockerl‐Goldstein, K., Kaya, H., Sebag, M., Samaras, C., Malek, E., Talamo, G., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16213 · Cited by 46
Peng, Y., Li, F., Zhang, P., Wang, X., Shen, Y., Feng, Y., Jia, Y., Zhang, R., Hu, J., & He, A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117503 · Cited by 42
Metadata
- Authors
- Robak, P., Drozdz, I., Szemraj, J., & Robak, T.
- Venue
- Cancer Treatment Reviews
- Publisher
- Elsevier BV
- Published
- 2018-11
- Volume
- 70
- Pages
- 199-208
- ISSN
- 0305-7372 (ISSN-L)
- OpenAlex
- W2889850156
- Cited by
- 283
- References
- 151
- FWCI
- 19.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.